Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Individual Molecular Minimal Residual Disease (MRD) Monitoring for Patients With MDS and Mixed MDS/MPN Treated With Allogeneic Stem Cell Transplantation

NCT02872662 is registered in ClinicalTrials.gov with Nordic MDS Group as lead sponsor.

NCT NCT02872662
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02872662 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Individual Molecular Minimal Residual Disease (MRD) Monitoring for Patients With MDS and Mixed MDS/MPN Treated With Allogeneic Stem Cell Transplantation
Lead sponsor
Nordic MDS Group
Phase
Observational
Overall status
Completed
Start date
August 31, 2016
Completion date
November 22, 2021
Enrollment
308 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

mds, mrd, sct